Tsukuba, Japan

Hirotoshi Adachi


Average Co-Inventor Count = 3.2

ph-index = 6

Forward Citations = 165(Granted Patents)


Company Filing History:


Years Active: 1999-2014

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Hirotoshi Adachi: Innovator in Transdermal Drug Delivery

Introduction

Hirotoshi Adachi is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceutical preparations, particularly in transdermal and transmucosal drug delivery systems. With a total of 10 patents to his name, Adachi's work has advanced the way medications are administered through the skin and mucous membranes.

Latest Patents

Among his latest patents, Adachi has developed an adjuvant or pharmaceutical preparation for transdermal or transmucosal administration. This innovative adjuvant comprises at least one substance selected from an aliphatic alcohol, a free fatty acid, and a fatty acid derivative, while excluding certain cyclic compounds. Additionally, he has created an iontophoresis device that is activated during use. This device is designed to supply a dissolution liquid in an amount that corresponds to the drug being used. It features an absorber made of a material containing a dry drug, a wall material with an adhesive layer, and a support with an opening, among other components.

Career Highlights

Hirotoshi Adachi has worked with notable companies such as Hisamitsu Pharmaceutical Company, Inc. and Kyodo Printing Co., Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and drug delivery technologies.

Collaborations

Throughout his career, Adachi has collaborated with esteemed colleagues, including Naruhito Higo and Seiji Tokumoto. These partnerships have contributed to the development of his groundbreaking inventions.

Conclusion

Hirotoshi Adachi's contributions to the field of transdermal drug delivery are noteworthy and impactful. His innovative patents and collaborations reflect his dedication to advancing pharmaceutical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…